The CEO's $9M open-market buy is a strong bullish signal from the highest-ranking insider, but it is contradicted by the company's own lowered guidance and massive restructuring plan. The cluster's dollar value is only 0.012% of market cap, which is trivial in proportional terms. Traders should watch for additional insider buying or selling in the coming weeks to confirm conviction, and monitor Q3 results for execution on the restructuring plan. The mixed signals suggest a wait-and-see approach until the next earnings release clarifies the trajectory.
Price Chart
Executive Summary
Boston Scientific CEO Michael Mahoney and Director David Habiger made open-market purchases totaling $9.1M, with the CEO alone buying $9.0M worth of shares at $48.33. This insider buying cluster follows a Q2 earnings beat that was overshadowed by a significant guidance cut and a $700M-$800M restructuring plan filed 14 days prior. The CEO's large personal investment signals confidence in the company's turnaround, but the material guidance reduction and restructuring charges create a conflicting picture for traders.
Key Financial Metrics
Key Facts
- CEO Michael Mahoney purchased 186,200 shares for $9.0M at $48.33 on 2026-08-03
- Director David Habiger purchased 2,100 shares for $100K at $47.59 on 2026-08-05
- Total insider buying cluster value: $9.1M, representing approximately 0.012% of $74.2B market cap
- CFO Jonathan Monson made a discretionary sale of 9,908 shares for ~$500K on 2026-08-10
- Q2 2026 EPS beat consensus by 3.6% ($0.86 vs $0.83) but full-year guidance was significantly lowered
- Full-year 2026 organic revenue growth guidance cut to 5-6% from prior 6.5-8%
- Adjusted EPS guidance reduced to $3.28-$3.32 from $3.34-$3.41
- Restructuring plan with $700M-$800M in charges announced on 2026-07-29
Financial Impact
CEO open-market purchase of $9.0M at $48.33 per share; total cluster buying $9.1M vs CFO sale of ~$500K; restructuring charges of $700M-$800M
Risk Factors
- Guidance cut signals deceleration in core business growth
- Restructuring with $700M-$800M charges could indicate deeper operational issues
- CFO's discretionary sale of $500K on 2026-08-10 may temper CEO's bullish signal
- Historical performance on BSX reports shows negative average T+20 returns (-7.43%)
- Insider buying at only 0.012% of market cap is proportionally insignificant despite large absolute dollar amount
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-BSX-1786526265663 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | Court Ruling | $48.30 $43.88 | ▼ −9.15% | ▼ −8.96% | $42.69 (−11.60%) |
Aug 26, 2026 5w ago | 8-K | $48.17 $43.72 | ▲ +9.24% | ▲ +10.44% | $42.69 (+11.37%) |
Aug 22, 2026 5w ago | Institutional Cluster | $49.01 $44.92 | ▼ −8.35% | ▼ −9.66% | $42.69 (−12.89%) |
Aug 7, 2026 8w ago | Insider Cluster | $49.31 $47.80 | ▼ −3.06% | ▼ −2.67% | $42.69 (−13.42%) |
Aug 7, 2026 8w ago | Insider Cluster | $49.31 $47.80 | ▼ −3.06% | ▼ −2.67% | $42.69 (−13.42%) |
Aug 5, 2026 8w ago | Insider Cluster | $47.74 $48.37 | ▲ +1.32% | ▲ +1.92% | $42.69 (−10.57%) |
Jul 29, 2026 9w ago | 8-K | $46.04 $48.17 | ▼ −4.63% | ▲ +0.39% | $42.69 (+7.27%) |
Jul 27, 2026 9w ago | 8-K | $46.06 $49.86 | ▲ +8.25% | ▲ +4.87% | $42.69 (−7.31%) |
Jul 27, 2026 9w ago | Court Ruling | $45.51 $49.01 | ▲ +7.69% | ▲ +4.39% | $42.69 (−6.19%) |
Jul 10, 2026 12w ago | Court Ruling | $44.77 $49.30 | ▲ +10.11% | ▲ +7.69% | $42.69 (−4.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access